Literature DB >> 2355217

Decreased ferritin levels in brain in Parkinson's disease.

D T Dexter1, A Carayon, M Vidailhet, M Ruberg, F Agid, Y Agid, A J Lees, F R Wells, P Jenner, C D Marsden.   

Abstract

Ferritin levels were measured in postmortem brain tissue from patients dying with Parkinson's disease [treated with L-3,4-dihydroxyphenylalanine (L-DOPA)] and from control patients. Ferritin levels were decreased in the substantia nigra, caudate-putamen, globus pallidus, cerebral cortex, and cerebellum when compared with age-matched control tissues. However, in CSF from L-DOPA-treated patients and in serum from L-DOPA-treated and untreated parkinsonian patients, ferritin levels were normal. Previous studies have suggested an increased total iron content in substantia nigra of parkinsonian brain. The failure of substantia nigra ferritin formation to be stimulated by increased iron levels suggests some defect in iron handling in this critical brain region in Parkinson's disease. The reason for decreased ferritin levels throughout the parkinsonian brain is not clear but does not seem to reflect a general system deficit in ferritin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2355217     DOI: 10.1111/j.1471-4159.1990.tb08814.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  37 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease.

Authors:  Julie K Andersen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 3.  Reactive oxygen species in the regulation of synaptic plasticity and memory.

Authors:  Cynthia A Massaad; Eric Klann
Journal:  Antioxid Redox Signal       Date:  2010-10-28       Impact factor: 8.401

4.  Neuroscience in Africa.

Authors:  Susan J van Rensburg; Brian Harvey
Journal:  Metab Brain Dis       Date:  2006-09       Impact factor: 3.584

5.  Characterization of brain beta-carboline-2-N-methyltransferase, an enzyme that may play a role in idiopathic Parkinson's disease.

Authors:  D A Gearhart; E J Neafsey; M A Collins
Journal:  Neurochem Res       Date:  1997-02       Impact factor: 3.996

6.  Specific Inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential etiological linkage to neurodegenerative diseases.

Authors:  Muralidhar L Hegde; Pavana M Hegde; Luis M F Holthauzen; Tapas K Hazra; K S Jagannatha Rao; Sankar Mitra
Journal:  J Biol Chem       Date:  2010-07-09       Impact factor: 5.157

7.  Serum iron, vitamin B12 and folic acid levels in Parkinson's disease.

Authors:  Gulizar Madenci; Sule Bilen; Berna Arli; Mustafa Saka; Fikri Ak
Journal:  Neurochem Res       Date:  2012-02-26       Impact factor: 3.996

Review 8.  Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review.

Authors:  Sara Pietracupa; Antonio Martin-Bastida; Paola Piccini
Journal:  Neurol Sci       Date:  2017-09-02       Impact factor: 3.307

9.  Distribution of ferritin in the rat hippocampus after kainate-induced neuronal injury.

Authors:  En Huang; Wei-Yi Ong
Journal:  Exp Brain Res       Date:  2004-11-20       Impact factor: 1.972

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.